BlackRock Inc. purchased a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ: INBS) duri

Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular s

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges

Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medica

Shares of Intelligent Bio Solutions are surging Monday after it announced a significant regulatory m

The recertification, issued by the British Standards Institution (BSI), is effective October 14, 202

Recertification aligns with the FDA's newly amended Quality Management System Regulation and support

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical t

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

Intelligent Bio Solutions (NASDAQ: INBS - Get Free Report) and Eurofins Scient (OTCMKTS:ERFSF - Get

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical t

Company has addressed final review items from penetration testing and finalized cybersecurity and so

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical t

Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and

The Company has again partnered with CenExel Clinical Research, Inc. to complete the clinical study.

Interference Study designed to validate system specificity in the presence of potentially interferin

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerpr

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerpr

Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(1.80) per share. This is a 59

Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, repres

Establishment Labs (NASDAQ: ESTA - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Ge

Aeon Global Health (OTCMKTS:AGHC - Get Free Report) and Intelligent Bio Solutions (NASDAQ: INBS - Ge

The study aims to improve the already rapid time-to-result of INBS's drug screening technology,

Validation study targets sub-3-minute results to capture global roadside testing market and signific

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical t

INBS implements enhanced security architecture to protect test integrity and donor data, strengtheni

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical t

Study results finalized on schedule  support FDA clearance and planned U.S. commercial launch Compan

Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical te

Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(2.82) per share. This is a 43

Clinical studies designed to support FDA clearance and planned commercial launch into the world'

INBS surged on strategic manufacturing partnership and revenue growth, but pulled back after announc